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FOREWORD 
 
 
Welcome again to the ninth edition of ESTEEM Academic Journal (Social Science and 
Technology issue). It also marks the second successive issue that Unit Penerbit, Universiti 
Teknologi MARA (Pulau Pinang) has published online journal in tandem with the marked 
growth of popularity among readers in electronic journals. Apart from that, it has made 
accessible the online journal in both PDF and EPUB files. It is hoped that these two formats 
will facilitate readers to view the content using different gadgets and options available to 
them. This will definitely advance the sharing of research materials and discussions between 
the authors and the wider fraternal scholars. 
 
ESTEEM Academic Journal 9(2) has also received overwhelming support from many authors 
from within UiTM main campus as well as from branch campuses and also likewise from 
other local public institutions. The Editorial Board has its hands full trying its level best to 
process as many articles as possible for the intended publication. It is therefore befitting that 
thanks should be accorded to all the relevant parties for making this publication of academic 
journal yet another reality. 
 
First and foremost, I would like to thank Associate Professor Mohd Zaki Abdullah, outgoing 
Rector of UiTM (Pulau Pinang), Associate Professor Ir. Hj. Bahardin Baharom, former 
Deputy Rector of Academic & International Affairs and Dr. Mohd Subri Tahir, Deputy Rector 
of Research, Industry, Community & Alumni Network for their selfless guidance and 
enduring support. Next, I would like to register my sincere thanks to the panel of reviewers, 
managing, language and formatting editors for toiling tirelessly through trying times in order 
to make this online journal more available to a wider academic community. Lastly, I would 
like to thank all the authors who have contributed their articles for consideration in ESTEEM 
Academic Journal and congratulate those who have had their articles published. I look 
forward to the continued firm support from all the concerned parties. To the readers and 
researchers alike, I once again hope that you will gain some insights and knowledge from 
reading these articles. 
 
Liaw Shun Chone 
Chief Editor 
ESTEEM Academic Journal 
Vol. 9, No. 2 (2013) 
(Social Sciences & Technology) 
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ABSTRACT 
Cell signalling is part of a strategy in drug discovery. Among the focus is by 
studying the insulin and insulin-like growth factor (IGF1R) signalling 
pathways. The molecular mechanism of insulin and IGF1R signalling pathways 
have been studied extensively. Both pathways are vital in many of the 
mechanisms in human body particularly in regulating the metabolism and cell 
growth. Besides, both pathways have been found to be involved in numerous 
diseases such as in various types of cancer. This review briefly revealed the 
information on the pathways, their correlations and current findings in cancer 
study. 
Keywords: cancers; cell signalling; insulin; insulin-like growth factor signalling pathways. 
1. INTRODUCTION 
Cell signalling is a cell-to-cell interaction or communication between the inter- and intra-cells. 
It is essential to monitor the cell environment and to respond to external stimuli. The cell 
signalling can trigger numerous effects including differentiation, proliferation, survival and 
other cellular functions for cell endurance. Thus, cell signalling has been applied as part of a 
strategy in drug discovery (Aggarwal, Sethi, Baladandayuthapani, Krishnan, & Shishodia, 
2007). One of such fascinating cell signalling is insulin and insulin-like growth factor (IGF) 
pathways. Alterations of the pathways have been associated with insulin resistance and other 
related diseases such as hyperinsulinaemia, hyperglycaemia, diabetes, and cardiovascular 
diseases (Frasca et al., 2008). Moreover, recent studies have revealed significant functions of 
insulin and IGF signalling pathways in several types of cancers including breast, colon, ovary 
and liver cancers (Clayton, Banerjee, Murray, & Renehan, 2011; Frasca et al., 2008; 
Giovannucci, 1995; Koohestani et al., 1998; Tran, Medline, & Bruce, 1996).  
Interestingly, the cancer is associated with type 2 diabetes or in other words, there are 
correlations between insulin and IGF signalling pathways with the disease (Hu et al., 1999; 
Michels et al., 2003; Yang, Hennessy, & Lewis, 2004). Perhaps, understanding the cell 
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signalling, i.e., insulin and IGF signalling pathways is a key in developing a more appropriate 
treatment for cancer (Chappell et al., 2001; Lindsay & Evans, 2008). 
1.1 Insulin Signalling Pathway 
Insulin signalling pathway is one of the examples of cell signalling in human body. It is 
classified according to distance signalling as an endocrine signalling and according to 
receptor signalling as tyrosine kinase, i.e., receptors with intrinsic enzymatic activity. It is 
considered as an endocrine receptor signalling as it involves the insulin hormone secreted by 
β-cells in islets of Langerhans in the pancreas. Meanwhile, it is also known as receptor 
tyrosine kinase signalling or as a phosphorylation of tyrosine amino acid on β-subunit of 
insulin receptor (IR) to regulate the signal transduction in cells. However, the latter 
classification is the most commonly applied (Kido, Nakae, & Accili, 2001; Leney & Tavare, 
2009).  
One of the major components in insulin signalling is IR. Discovery of the IR by Roth and 
colleagues in 1971 has created a new paradigm in understanding the molecular basis of 
insulin action which is involved with other molecular signalling such as insulin receptor 
substrate 1(IRS-1), Src homology 2 (SH2) domains, phosphoinositide 3-kinase (PI3-K), PIP3-
dependent protein kinases (PDK), Protein Kinase B (PKB) or also known as AKT and glucose 
transporter 4 (GLUT4) (Ismail, King, & Pillay, 2009; Leney & Tavare, 2009).  
IR is located on the chromosome 19. The expression is detected during embryonic and in 
adulthood stages (Kido et al., 2001). Basically, the IR is a heterotetrameric structure that 
contains two α- and two β-subunits receptor that plays a key role in providing insulin binding 
site. The intracellular receptor consists of ligand-activated tyrosine kinase that facilitates the 
docking site for downstream molecules. IR is classified into two isoforms, i.e., IR fetal 
isoform A (IR-A) and B (IR-B) (Frasca et al., 2008). Moreover, it also exists in a hybrid form 
with IGF receptor 1 (IGF1R). The major ligand is insulin but in certain cases, it also has an 
affinity to insulin-like growth factor II (IGF-II) ligand (Frasca et al., 2008; Menting et al., 
2013). 
The primary function of the insulin signalling pathway is to regulate the glucose metabolism 
homeostasis (glucose intake and storage) in human body (Leney & Tavare, 2009). Thus, IR is 
mostly expressed in insulin-sensitive tissues such as skeletal muscle, liver and adipose tissues. 
Other than that, numerous studies have revealed that the pathway is also involved in the cell 
growth promotion in-vitro and in-vivo, and in cancer development (Aleem, Nehrbass, Klimek, 
Mayer, & Bannasch, 2011; Frasca et al., 2008; Clayton et al., 2011; Friedrichs et al., 2008; 
Heuson, Legros, & Heimann, 1972; Novosyadlyy et al., 2010; Nunez et al., 2006; Shafie & 
Hilf, 1981). In the latter function, IR-A is involved as it has the peculiar characteristic to bind 
not only to insulin but also to IGF-II (Frasca et al., 2008).  
1.2 Insulin-Like Growth Factor (IGF)  
The insulin-like growth factor (IGF) was first discovered by Salmon and Daughaday in 1957 
(Bruchim, Attias, & Werner, 2009; Werner, Weinstein, & Bentov, 2008). It is another 
endocrine signalling which mediates the growth hormone (GH) to induce metabolic and 
anabolic processes in human body. It is a polypeptide that acts in a paracrine and autocrine 
manner which is involved in the growth, apoptosis, differentiation and transformation of cells 
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(Lindsay & Evans, 2008; Moschos & Mantozoros, 2002). Other than that, it is also classified 
under the receptor tyrosine kinase signalling pathway which is similar to insulin signalling 
pathway i.e. require tyrosine phosphorylation on receptors prior to the downstream signal 
transduction IGF system contains two growth factors (IGF-1 and IGF-II), two cell surface 
receptors (IGF-1R and IGF-IIR) and six specific binding proteins (IGFBP-1 to IGFBP-6) (Le 
Roith, 2003).  
IGF-I is located on the chromosome 12q22. IGF-I expression is low during the embryonic 
stage and plays an important role in growth and development. IGFs is a system involving 
hormones, cell surface receptors and binding proteins that control normal growth and 
differentiation of most organs and this system is active at most stages of the life cycle which 
includes the fetal period, infancy and adulthood (Bruchim et al., 2009).  Thus, IGF1R is 
expressed in almost all body tissues (Le Roith., 2003). IGF displays biological activities at 
both cell and organism levels, function as cell progression factors and pushing cell through 
various phases of the cell cycle at cellular level, while at the organism level; it participates in 
the control of multiple systems, such as neuronal activity, kidney function and reproduction 
(Bruchim et al., 2009). 
Moreover, the IGF system is evident in the cancer development and progression since IGF 
shows common events in several malignancies including IGF-IR over-expression and over-
activation and production of IGF-IR ligands (IGF-I and II) (Frasca et al., 2008; Khandwala, 
McCutcheon, Flyvbjerg, & Friend, 2000). IGF-1 can act as a potential growth factor in cancer 
cells and it can also promote tumorgenesis (Hadsell et al., 2000; Gunter et al., 2009). Down-
regulation of IGF-1 inhibits the progression of tumorgenesis (Hadsell et al., 2000; Wu et al., 
2003). Epidemiological studies also show a high level of IGF-1 in colorectal, prostate and 
breast cancer.  
1.3 Synergetic Effects Of Insulin And Insulin-Like Growth Factor (IGF) System 
Insulin and insulin-like growth factor system (IGFs) are growth factors that were thought only 
to be involved in glucose metabolism and in the activation of cellular signalling cascades 
mediating cell proliferation, differentiation, and survival (Cannata, Fierz, Vijayakumar, & 
LeRoith, 2010; Nakae, Kido, & Accili, 2001).  However, several studies suggest that insulin 
also exhibited a number of IGF-I like activities such as growth stimulation (Cannata et al., 
2010; Werner et al., 2008).  It is because even though insulin and IGF have different 
functions, both share the same downstream cascade which involves various networks and 
pathways (Figure 1). 
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Figure 1: Downstream Cascades Regulation By IR And IGF-1R. 
Moreover, insulin and IGF receptors share remarkable similarities in term of structures, 
genetic and downstream cascades activities (Cannata et al., 2010; Werner et al., 2008).  Both 
IGF-1R and IR are known as members of the ligand-activated receptor kinase super family, 
once they are activated by the ligands, they will undergo conformational changes which lead 
to ATP binding and autophosphorylation of the tyrosine kinase domain (Werner et al., 2008) 
(Figure 1). This will enhance the kinase activity of the receptors and confers upon them the 
ability to phosphorylate a series of cytoplasmic substrates, collectively known as downstream 
signal transduction mediators (Werner et al., 2008).   
Other than that, both insulin receptor and IGF-1 receptor can be activated by insulin binding. 
The insulin could enhance IGF signalling by directly stimulating the IGF-1R receptor. 
However the signalling by insulin activation of IGF-1 receptor will lead to growth promotion 
and cell proliferation (Khandwala et al., 2000). 
Similarities between both IR and IGF-1R might be due to the fact that both are synthesized as 
single polypeptide chains that are processed to produce glycopeptides of Mr 180 kDa (Werner 
et al., 2008).  After the translational process, a mature heterotetrameric with β-α-α-β 
conformation is produced with the α-subunit residing entirely in the extracellular with the 
cysteine-rich region and several N-linked glycosylation sites (Werner et al., 2008).   
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The remarkable similarity between IGF-1R and IR in terms of structure and genomic 
information is consistent with the theory that both receptor genes share a common 
evolutionary origin (Werner et al., 2008).  Originally, both IR and IGF-1R are thought to bind 
only towards their specific ligands at high affinities, however, the existence of 2 isoforms of 
IR portray a new understanding on both insulin and IGF system (Mosthaf et al., 1990; Werner 
et al., 2008).  
The two isoforms of IR (IR-A and IR-B) are formed from the alternative splicing of the IR 
transcript. IR-A mediates the anti-apoptotic and mitogenic effects, whereas IR-B exerts 
metabolic effects (Sciacca et al., 2003).  IR-A binds to IGF-II and insulin, meanwhile IR-B is 
poorly responsive towards IGF-II (Cannata et al., 2010).  Since IGF-II is a powerful 
stimulator of cell proliferation, the ability of IR-A to bind to IGF-II may explain the 
difference in cell signalling of the two isoforms (Cannata et al., 2010).  Insulin and IGF-I bind 
to their own cognate receptor with the highest affinity (Cannata et al., 2010).  
Because there is a high degree of homology, IGF-1R and IR can form hybrid receptors 
consisting of 1 α-subunit and 1 β-subunit of IR, and 1 α-subunit and 1 β-subunit of IGF-1R 
(Cannata et al., 2010) (Figure 2).   This hybrid receptors behave more like IGF-1R compared 
to IR due to their high affinity towards IGF-I rather than insulin. Therefore, the hybrid 
receptors provide additional binding sites for IGF-I and leads to increased cell sensitivity to 
IGF-I (Cannata et al., 2010). 
 
Figure 2: Insulin Receptor, Insulin-Like Growth Factor 1 Receptor (IGF-1R) And Hybrid Insulin-Like Growth 
Factor 1 Receptor. 
Both insulin and insulin-like growth factor 1 (IGF-1) trigger complex downstream cascade 
such as the PI3K pathway, and the mitogen-activated protein kinase (MAPK) pathway 
(Samani, Yakar, LeRoith, & Brodt, 2007).  The PI3K activation promotes PKB pathway 
(Taha & Klip, 1999) and PI3K/PKB pathway whereas MAPK pathway promotes cell growth 
and has an anti-apoptotic effect (Frasca et al., 2008; Saltiel & Kahn, 2001).   
A huge component of these pathways are shared by both IR and IGF-1R and a number of 
potential mechanisms were proposed to explain how these two receptors succeed in engaging 
different biological activities (Werner et al., 2008).  These mechanisms include different 
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tissues distributions of IR and IGF-1R, different internalization kinetics and sub cellular 
distributions of the hormone receptor complex, and different hormones receptor affinities 
(Werner et al., 2008). 
2. CONCLUSION 
Current studies on insulin and IGF signalling pathways have discovered the importance of 
both pathways in regulating metabolic and mitogenic effects in the body. Better understanding 
particularly on the molecular mechanism of cancer and type 2 diabetes via the insulin and IGF 
signalling pathways may provide a constructive key in developing an effective drug in the 
future. 
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